Progenics Pharmaceuticals Inc. (PGNX) financial statements (2022 and earlier)

Company profile

Business Address ONE WORLD TRADE CENTER
NEW YORK, NY 10007
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments42,049137,68690,642138,90974,103119,30265,860
Cash and cash equivalents42,049137,68690,642138,90974,103119,30265,860
Receivables15,9763,8033,9724,8643,5431092,879
Other current assets5,7072,6402,2564,3285,6392,5151,943
Total current assets:63,732144,12996,870148,10183,285121,92670,682
Noncurrent Assets
Operating lease, right-of-use asset13,493
Property, plant and equipment11,6883,9444,1224,7602,4072,5522,413
Long-term investments and receivables      2,208
Long-term investments      2,208
Intangible assets, net (including goodwill)24,67019,74043,44343,65543,86736,40239,081
Goodwill17,84713,07413,07413,07413,0747,7027,702
Intangible assets, net (excluding goodwill)6,8236,66630,36930,58130,79328,70031,379
Other noncurrent assets5,8871,6841,5222,4701,692157157
Total noncurrent assets:55,73825,36849,08750,88547,96639,11143,859
TOTAL ASSETS:119,470169,497145,957198,986131,251161,037114,541
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:14,35210,97712,91416,3319,5446,5706,512
Accounts payable1,2494443,3595674521,040793
Accrued liabilities13,10310,5339,55515,7644,2871,146 
Employee-related liabilities    1,8451,7222,123
Other undisclosed accounts payable and accrued liabilities    2,9602,6623,596
Debt7,7165,4192,445    
Business combination, contingent consideration, liability 7,050    
Other liabilities   26185115115
Total current liabilities:22,06823,44615,35916,3579,7296,6856,627
Noncurrent Liabilities
Long-term debt and lease obligation46,91539,18047,24249,453   
Long-term debt, excluding current maturities31,91039,18047,24249,453   
Operating lease, liability15,005
Liabilities, other than long-term debt3,9345,76819,55316,28020,06418,447914
Deferred revenue and credits1,225876402336 
Deferred income tax liabilities34
Other liabilities 1,8181,5281,204862911914
Business combination, contingent consideration, liability3,9003,95016,80014,20018,80017,200
Other undisclosed noncurrent liabilities 2835012,13410,79710,99628,021
Total noncurrent liabilities:50,84944,97667,14577,86730,86129,44328,935
Total liabilities:72,91768,42282,50494,22440,59036,12835,562
Stockholders' equity
Stockholders' equity attributable to parent46,553101,07563,453104,76290,456124,90978,979
Common stock1131109392919179
Treasury stock, value(2,741)(2,741)(2,741)(2,741)(2,741)(2,741)(2,741)
Common stock, share subscribed but unissued, subscriptions receivable  (2,109)    
Additional paid in capital727,089713,019609,829598,069594,511589,826548,510
Accumulated other comprehensive loss(148)(105)(33)(85)(26) (192)
Accumulated deficit(677,760)(609,208)(541,586)(490,573)(501,379)(462,267)(466,677)
Stockholders' equity attributable to noncontrolling interest    205  
Total stockholders' equity:46,553101,07563,453104,76290,661124,90978,979
TOTAL LIABILITIES AND EQUITY:119,470169,497145,957198,986131,251161,037114,541

Income statement (P&L) ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues34,98615,62211,69869,4298,67644,3777,862
Revenue, net11,69869,4298,67644,3775,992
Other operating income     7,250 
Cost of revenue(4,084)    (498)(567)
Cost of goods and services sold(3,168)    (498)(567)
Gross profit:30,90215,62211,69869,4298,67643,8797,295
Operating expenses(97,061)(81,978)(70,098)(56,325)(47,980)(48,257)(50,842)
Other undisclosed operating income     7,748567
Operating income (loss):(66,159)(66,356)(58,400)13,104(39,304)3,370(42,980)
Nonoperating income (expense)(2,376)(2,933)(4,285)(527)525146
Investment income, nonoperating    525146
Income (loss) from continuing operations before income taxes:(68,535)(69,289)(62,685)12,577(39,252)3,421(42,934)
Income tax expense (benefit)(17)1,63211,672(1,844)133989362
Net income (loss):(68,552)(67,657)(51,013)10,733(39,119)4,410(42,572)
Net income attributable to noncontrolling interest   737  
Net income (loss) available to common stockholders, diluted:(68,552)(67,657)(51,013)10,806(39,112)4,410(42,572)

Comprehensive Income ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net income (loss):(68,552)(67,657)(51,013)10,733(39,119)4,410(42,572)
Other comprehensive income (loss)   (62)(26)19268
Other undisclosed comprehensive income (loss) (72)52    
Comprehensive income (loss):(68,552)(67,729)(50,961)10,671(39,145)4,602(42,504)
Comprehensive income, net of tax, attributable to noncontrolling interest   737  
Other undisclosed comprehensive loss, net of tax, attributable to parent(43)      
Comprehensive income (loss), net of tax, attributable to parent:(68,595)(67,729)(50,961)10,744(39,138)4,602(42,504)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: